Risk-reducing Surgery in BRCA mutation carriers
|
|
- Melvin Craig
- 5 years ago
- Views:
Transcription
1 Risk-reducing Surgery in BRCA mutation carriers Daerim St. Mary s Hospital Department of Surgery, Breast Care Center Hereditary Breast Ovarian Cancer Clinic Sung-Won Kim, MD, PhD, FACS
2 Overview of HBOC Risk-reducing surgery Where are we in Asia Contents Patterns of HBOC Management in Korea Korean Hereditary Breast Cancer (KOHBRA) St udy
3 Hereditary Breast Ovarian Cancer New York Times ( ) My Medical Choice
4 BRCA carriers or Even Non-carriers TO REMOVE OR NOT TO REMOVE BREAST???? THAT IS THE PROBLEM!!!
5
6 Breast-Cancer Susceptibility Loci and Genes Foulkes et al. NEJM 2008
7 Breast and ovarian cancer risk in BRCA1/2 mutation carriers BRCA1 BRCA2 BRCA 1 BRCA 2 Breast cancer ( ) 65% (44%-78%) 45% (31%-56%) Ovarian cancer ( ) 39% (18%-54%) 11% (2.4%-7.9%) Antoniou et al. Am J Mum Genet 2003
8 Environmental modifiers of breast cancer risk among mutation carriers Breast feeding Late menarche Pregnancy Study BRCA1 BRCA2 Kotsopoulos et al., 2012 Jernstrom et al., 2004 Kotsopoulos et al., 2005 Cullinance et al., 2005 Kotsopoulos et al., 2007 Protective At least 1 year: 32% reduction, 2 years and more: 49% reduction Protective At least 1 year: 45% reduction Protective >14 y vs. 11 y: 54% reduction 4 births (only a modest protective effect) Early full-term birth: not protective No association No association No association Increase in cancer risk with each additional pregnancy (OR=1.17, 95%CI: ) Early full-term birth: not protective
9 Genetic modifiers of breast cancer risk among mutation carriers SNPs associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers (GWAS) Milne & Antoniou. Ann Oncol 2011
10 Screening for breast cancer Kriege et al., NEJM 2004 MRI is more sensitive than MMG AUC for MMG: AUC for MRI: Warner et al., JCO 2011 Incidence of advanced breast cancer was decreased by 70% in women with MRI screening Early (0-I) Total Advanced (II-IV)
11 Chemoprevention of breast cancer King et al. JAMA 2001 NSABP P-1 trial, subset analysis Tamoxifen reduced breast cancer incidence only among healthy BRCA2 carriers Gronwald et al. Int J Cancer 2006 Tamoxifen and contralateral breast cancer in BRCA1/2 carriers (update)
12 Risk Reduction Intervention Risk reduction surgery - Risk-reduction mastectomy (RRM) - RRM: 90% BC risk-reduction in BRCA carriers No evidence of life-expectancy gain NCCN Breast Cancer Risk Reduction Panel supports the use of RRM for carefully selected women at high risk of breast cance r who desire this intervention women with a BRCA1/2, TP53, or PTEN mutation or, possibly, for women with a history of LCI S
13 Risk Reduction Intervention Risk reduction surgery - Bilateral salpingo-oophorectomy - Rationale for RRSO Absence of reliable methods of early detection Poor prognosis associated with advanced ovarian cancer RRSO 80% reduction in the risk of ovarian or fallopian tube cancer PPC: 3% residual risk of a primary peritoneal carcinoma Also reduce the risk of BC by approximately 50%.
14 PROSE Consortium Study Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations RRM: lower risk of breast cancer RRSO: lower risk of ovarian cancer, first diagnosis of breast cancer, allcause mortality, breast cancer specific mortality, and ovarian cancer specific mortality. RRSO and breast cancer risk in healthy carriers Risk reduction 1 ( ) HR: 0.54 ( ) HR: 0.63 ( ) HR: 0.36 Domchek et al. JAMA 2010
15 PROSE Consortium Study Prospective, multicenter cohort study of 2482 women with BRCA1 or BRCA2 mutations RRSO and all-cause mortality 1 ( ) HR: 0.4 Risk reduction ( ) ( ) HR: 0.52 HR: 0.38 Domchek et al. JAMA 2010
16 Manchester Study Manchester Genetic Medicine DB 691 female healthy BRCA1/2 mutation carriers; 346 BRCA1 and 345 BRCA2. Ingham et al. BCRT 2013;142:611
17 Dutch Study 570 healthy female mutation carriers (405 BRC A1, 165 BRCA2) BRRM: 156 BRCA1 and 56 BRCA2 carriers HR of 0.29 (95% CI ) for BC-specific m ortality. Heemskerk-Gerristsen et al. Ann Oncolo 2013;24:2029
18 Contralateral RRM Survival from the primary breast cancer in 105 contralateral risk-reducing mastectomy (CRRM) cases vs. 105 non-crrm controls Hazard ratio 0.37 (95% CI ), p= years survival: 89% in CRRM vs. 73% in no-crrm CRRM improves survival in women with BRCA1/2- associated breast cancer Evans et al. Breast Cancer Res Treat 2013
19 Contralateral RRM Contralateral mastectomy and survival after breast cancer in carr iers of BRCA1 and BRCA2 mutations: retrospective analysis 390 female (I, II BC) BRCA+ 181 CRRM Median f/u: 14.3 years 20 year survival rate 88% vs. 66% with CRRM HR: 0.52 (p=0.08) Metcalfe et al. BMJ 2014
20 Contralateral RRM Improved overall survival after contralateral risk-reducing mastec tomy in brca1/2 mutation carriers with a history of unilateral bre ast cancer: A prospective analysis Dutch multicentre cohort 583 BRCA-associated PBC patients (1980~2011) 242 pt. (42%) CRRM vs. 341 pt. (58%) Surveillance Median follow-up after PBC diagnosis was 11.4 years CBC incidence: CRRM (2%) vs. Surveillance (19%) (p < 0.001) Mortality: CRRM vs. Surveillance (9.6 and 21.6 per 1000 person-years of observatio n, respectively; adjusted hazard ratio 0.49, 95% confidence interval ). Survival benefit was especially seen in young PBC patients (<40 years), in patients having a PBC with differentiation grade 1/2 and/or no triple-negative phenotype, a nd in patients not treated with adjuvant chemotherapy. Bernadette et al. Int J Cancer 2014
21 Contralateral RRM Bernadette et al. Int J Cancer 2014
22 Where are we in Asia
23 ABRCA (Asian BRCA Consortium) in 2009 Oct Participants Korea (KOHBRA study, headquarter), Japan, Hong Kong, Malaysia, Indonesia, China, Singapore Objectives To share the knowledge of HBOC in Asian country To improve the quality of care of HBOC patients in Asia To collaborate for researches on HBOC in Asia Research collaboration BRCA registry Blood and tissue banking Clinical practice guideline
24 Summary of Projects of ABRCA consortium WG1 BRCA spectrum in Asia Review on BRCA in Asia (mutation spectrum, founder mutation, VUS) Database of BRCA and other non-brca genes (next phase) Classification of selected VUS by multifactorial approach WG2 Genetic and environmental modifiers Estimation of penetrance in Asian BRCA carriers Lifestyle modifiers in Asian BRCA carriers: development of pan-asian questionnaire Calibrating risk assessment in Asians using BOADICEA WG3 Management of HBOC Descriptive paper on the status of genetic counseling and genetic testing in Asian countries Outcomes for Asian BRCA carriers
25 BMJ May 22: Hurley R.
26 Ongoing ABRCA Project Asian mutation spectrum paper: Ava Kwong Genetic counseling and management in Asia: Seigo Nakamura Pan-Asian BRCA database: Sue K. Park
27 International consortium for HBOC
28 IBCCS (International BRCA1/2 Carrier Cohort study) Collaborative study of women and man carrying a deleterious mutation in BRCA1 or BRCA2 (1997~) Participating: 15 countries (19 groups) Specific aims 1. more precisely estimate the age-, sex-, and site-specific cancer risks due to mutations in the BRCA1 and BRCA2 genes; 2. assess the importance of risk factors as known in the general population, in determining the cancer risks in the BRCA1/2 mutation carriers; 3. examine the efficacy of prophylactic surgery and other screening/prevention options in these high risk women; 4. create an ongoing registry of gene carriers for potential use in future clinical trials
29 CIMBA (Consortium of investigators of modifiers of BRCA1/2) A collaborative group of researchers working on genetic modifiers of cancer in BRCA1 and BRCA2 mutation carriers The aim of CIMBA To provide sufficient sample sizes to allow large scale studies in order to evaluate reliably the effects of genetic modifiers Participating: 59 Study groups including KOHBRA Study 36 publications Polymorphism in IRS1 6p22.33 PHB 1630 C>T, MTHFR 677C>T
30 ENIGMA (Evidence-based network for the interpretation of germline mutant alleles) A consortium of investigators focused on determining the involvement of all unclassified variants (UV) in the BRCA1 and BRCA2 tumor suppressor genes The purpose To facilitate classification of variants through collaborative large-scale projects by sharing data and improving classification methods
31 Patterns of HBOC Management in Korea
32 Breast cancer; Age-Standardized Incidence Rate per 100,000 Most Common Cancer of Women GLOBOCAN Vary Between Areas Relatively Lower in Asia
33 Number American White Japanese (2001) Korean (2006) Age * patients number per 100,000 women SEER 17 data ( ) Cancer statistics in Japan (2007)
34 Number Year
35 BRCA Testing Reimbursement Since Aug 2005/Revised From May 2012 Breast or ovarian cancer patients who have more than one family members with breast or ovarian cancer Breast and ovarian cancer in one patient Early-onset breast cancer (age <40) Bilateral breast cancer Multiple organ cancer including breast cancer Male breast cancer Epithelial ovarian cancer Testing fee: 1,000 USD patient pays 100 USD
36 National Survey May from 36 institutions Follow-up version of 2007 survey. (2007 KOHBRA start!) Annual summary (2012) Genetic counseling: 1858 cases Genetic testing: 1318 cases Family history taking Pedigree drawing Genetic test availability Genetic test recommendation
37 Management of BRCA Mutation Carriers Recommendation N of hospitals % 1200 MRI Yes No Unknown Tamoxifen Yes No Unknown Oral pill Yes No Unknown BPM Yes No Unknown CPM Yes No Unknown BSO Yes No Unknown n=0-324
38 Genetic Counseling in SNUBH Genetic counseling 1132 Test acceptance (Overall) 982/1132 (86.7%) Test acceptance (Proband) 777/926 (83.9%) Test acceptance (Family member) 205/206 (99.5%) Test acceptance rate before and after reimbursement (only proband included) Before After 43/67 (64.2%) 734/859 (85.4%)
39 RRM rate in SNUBH NO cases of BRRM for 48 unaffected BRCA carriers CRRM: Of 102 unilateral BC female carriers Affected carriers: 8/102 (7.8%) Breast reconstruction: 5/8 (62.5%) CRRM date First Surgery First Surgery Name Genetic testing Test result Rt. BCS+SLNB Rt. BCS+SLNB Rt. BCS+ALND Lt. BCS+SLNB Rt. TM+SLNB+TEI Rt. BCS+ALND Lt. BCS+ALND Rt. BCS+SLNBx
40 RRSO rate in SNUBH N=145 (117 BC, 28 Healthy) BRCA mutation carriers (>35) RRSO rate Overall: 29.6% (43/145) for overall Affected carriers: 34.4% (41/119) Healthy carriers: 7.6% (2/26) Decision to undergo RRSO had been 16 months (range, 0 68 months) in the 43 carriers who had undergone RRSO
41 KOHBRA Study Overview
42 Korean Hereditary Breast Cancer Study (KOHBRA study) KOHBRA I : KOHBRA II : Multi-center study which is conducted by KBCS Grant: the National R&D Program for Cancer Control
43 KOHBRA Phase 1 Study aim: To define prevalence of BRCA1/2 mutation in Korea Korean Breast Cancer Study Group (KBCSG) Prospective nationwide study ~ Part I: Family Hx(+) Part II: FHx(-) & high risk group 1.Age at Dx.<40 2.Coexistence of ovary ca. 3.Male breast ca. 4.Bilateral breast ca. Part III: family member of BRCA(+) Part IV: Female from Part I, II, III (ovary ca prevalence)
44 Enrollment ( ~ ) Subgroups Total Familial breast cancer patients 1342 High-risk non-familial breast cancer 1342 Family members of carriers 553 Total enrollment 3237 Banking (WB, DNA, Serum, Plasma) 3183 BRCA Carriers 684
45 KOHBRA cohort Demographic information Clinical information Bank of DNA, serum KOHBRA Phase 2
46 KOHBRA Phase 2 (2010.6~2013.5) Development of Korean BRCA Prediction Model Part I (Risk prediction) Part 2 (Treatment) Characterization of clinical phenotype and discovery of novel prognostic factors for BRCA associated breast cancer Development of nationwide network of genetic counseling Part 4 (Genetic counseling) Part 3 (Prevention) Identification of environmental and genetic modifiers of BRCA1/2 mutation
47 KOHBRA Study Novel Gene Penetrance Intervention study Segregation analysis Family association study Virtual Counselor Modifier gene assay Gene-Env. Interaction Clinical Practice Guideline BRCA Mutation Risk Pretest Prediction Model BRCA Carrier Cohort Prevalence Study
48 Acknowledgement ABRCA Members KOHBRA Members
49 Thank you.
Role of Genetic Counseling Nurse in Breast Cancer. Sung-Won Kim, MD, PhD, FACS CEO & President Daerim St. Mary s Hospital
Role of Genetic Counseling Nurse in Breast Cancer Sung-Won Kim, MD, PhD, FACS CEO & President Daerim St. Mary s Hospital What is hereditary breast cancer? Hereditary (5-10%): Mutated phenotype of a specific
More informationManagement of BRCA mutation carriers
Management of BRCA mutation carriers Clinical Case Presentation Shani Paluch-Shimon, MBBS, MSc Head, Breast Cancer Service for Young Women Oncology Institute Sheba Medical Center, Israel esmo.org DISCLOSURES
More informationOverview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation
Overview of peculiarities and therapeutic options for patients with breast cancer and a BRCA germline mutation Dr Niklas Loman PhD MD Consultant oncologist Skåne University Hospital Lund, Suecia Prognosis
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More informationInherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions
Inherited Breast and Ovarian Cancer: 20 Years of Progress and Future Directions Noah D. Kauff, MD, FACOG Director, Clinical Cancer Genetics Duke Cancer Institute / Duke University Health System Disclosures
More informationGenetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction
Genetics of Breast and Ovarian Cancer: Risk Assessment, Screening, and Risk Reduction Forum INCA-ASCO sobre Cancer Hereditario e Predisposicao Genetica ao Cancer Jeffrey N. Weitzel, M.D. Professor of Oncology
More informationHBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond.
HBOC Syndrome A review of BRCA 1/2 testing, Cancer Risk Assessment, Counseling and Beyond. Conni Murphy, ARNP Cancer Risk Assessment and Genetics Program Jupiter Medical Center Learning Objectives Identify
More informationHereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with
Hereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with positive and negative results? SAMO Workshop Luzern 3./4.10.2014 Dr. med. Barbara Bolliger TumorTumor-
More informationBreast Cancer Risk and Prevention
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Version 2003: Kiechle / Schmutzler Versions 2004 2011:
More informationGermline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues
Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Timeline of Important Events in DNA Patenting (Top) and
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationBreast Cancer Risk and Prevention
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Risk and Prevention Breast Cancer Risk and Prevention Versions 2003 2012: Schmutzler with Albert / Blohmer /
More informationOverview of Inherited Cancer
Sidorela Gllava Overview of Inherited Cancer 52% 32% 16% BRCA 1 BRCA 2 Other Genes Breast Cancer: p53, PTEN, etc Ovarian Cancer:MSH2, MSH6, MLH1, etc Breast and Ovarian Cancer Risk: BRCA Mutation Carriers
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationSurgical treatment of BRCA mutated patients. Viviana Galimberti MD European Institute of Oncology Milan, Italy
Surgical treatment of BRCA mutated patients Viviana Galimberti MD European Institute of Oncology Milan, Italy No pharmaceutical company funding was used I declare I have no conflicts of interest as regards
More informationEffect of Oophorectomy on Survival After Breast Cancer
Research Original Investigation Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, PhD; Henry T. Lynch, MD; William D. Foulkes, MBBS, PhD; Nadine
More informationChristine Garcia, MD 1, Liisa Lyon, MS 2, Ramey D. Littell, MD 1 and C. Bethan Powell, MD 1
American College of Medical Genetics and Genomics Comparison of risk management strategies between women positive for a BRCA variant of unknown significance and women with known BRCA deleterious mutations
More informationPanel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research
Panel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research Malaysia E mail: soohwang.teo@cancerresearch.my How much of
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationSo, now, that we have reviewed some basics of cancer genetics I will provide an overview of some common syndromes.
Hello. My name is Maureen Mork and I m a Certified Genetic Counselor in the Clinical Cancer Genetics Program at The University of Texas MD Anderson Cancer Center. I ll be lecturing today on the Cancer
More informationUtilization of BRCA Testing. Breast and Ovarian Cancer in Texas
Utilization of BRCA Testing in Older Ode Women with Breast and Ovarian Cancer in Texas Ana M. Rodriguez, MD Assistant Professor Department of Obstetrics and Gynecology University of Texas Medical Branch
More informationSo, Who are the appropriate individuals that should consider genetic counseling and genetic testing?
Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary
More informationBRCA2 gene. Associated Syndrome Name: Hereditary Breast and Ovarian Cancer syndrome (HBOC) BRCA2 Summary Cancer Risk Table. BRCA2 gene Overview
BRCA gene Associated Syndrome Name: Hereditary Breast and Cancer syndrome (HBOC) BRCA Summary Cancer Risk Table Male Breast GENETIC RISK Female Breast Elevated Risk Elevated Risk BRCA gene Overview Hereditary
More informationBSO, HRT, and ERT. No relevant financial disclosures
BSO, HRT, and ERT Jubilee Brown, MD Professor & Associate Director, Gynecologic Oncology Levine Cancer Institute at the Carolinas HealthCare System Charlotte, North Carolina No relevant financial disclosures
More informationGermline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues
Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Risk Factors for Breast Cancer Aging Family history Early
More informationKey Recommendations. Gynecologic management of women with inherited risk of gynecologic cancer
Gynecologic management of women with inherited risk of gynecologic cancer C. Bethan Powell MD Kaiser Permanente Northern California Gynecologic Oncology Program Lead, Kaiser Permanente Northern California
More informationSpectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer
Spectrum of Care Options for Women at High Risk for Breast and Ovarian Cancer Sheryl G.A. Gabram, MD, MBA, FACS Professor of Surgery, Emory University Director, High Risk Assessment Program Winship Cancer
More informationBRCA Precertification Information Request Form
BRCA Precertification Information Request Form Failure to complete this form in its entirety may result in the delay of review. Fax to: BRCA Precertification Department Fax number: 1-860-975-9126 Section
More informationCase Presentation and Discussion: Breast Cancer. Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center
Case Presentation and Discussion: Breast Cancer Madhuri Rao, MD PGY-5 SUNY Downstate Medical Center Case Presentation 37 y/o female PMH/PSH: nil Meds: nil NKDA Family Hx: Sister died in early 30 s from
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationHereditary Gynecologic Cancer 15 Years of Progress
Hereditary Gynecologic Cancer 15 Years of Progress Bethan Powell, M. D. Kaiser Permanente UCSF Gynecologic Cancer Risk Program Hereditary Gynecologic Cancer Syndromes BRCA 1 and 2: ovarian Lynch: ovarian/endometrial
More informationRisk Assessment, Genetics, and Prevention
Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 09/01/2015 Section: Surgery Place(s) of Service:
More information1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45
1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women
More informationAccepted Preprint first posted on 15 August 2016 as Manuscript ERC
Page 1 of 28 Accepted Preprint first posted on 15 August 2016 as Manuscript ERC-16-0277 1 Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. 2 3 Roger L. Milne 1,2 and
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? A Patient s Guide to Hereditary Breast and Ovarian Cancer Syndrome What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 07/22/2011 Section: Surgery Place(s) of Service: Inpatient I.
More informationHost Factors that Increase Breast Cancer Risk
Host Factors that Increase Breast Cancer Risk 30 th Annual Miami Breast Cancer Conference March 7-10, 2013 Debu Tripathy, MD Professor of Medicine University of Southern California Norris Comprehensive
More informationGermline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues
Germline Mutations Hereditary Breast and Ovarian Cancer Risk and Management Issues Jeffrey N. Weitzel, M.D. Cancer Screening & Prevention Program Risks Related to Breast Cancer Advancing Age! Early Menarche!
More informationRisk Reduction management for Ovarian Cancer in Women with BRCA1/2 Mutation
Risk Reduction management for Ovarian Cancer in Women with BRCA1/2 Mutation Global Breast Cancer Conference 2018 2018. 4. 6 (Fri) Songdo, Incheon, Korea Hereditary Gynecologic Cancer Clinic Precision Medicine
More informationPrecision Medicine and Genetic Counseling : Is Yes always the correct answer?
Precision Medicine and Genetic Counseling : Is Yes always the correct answer? Beverly M. Yashar, MS, PhD, CGC Director, Graduate Program in Genetic Counseling Professor, Department of Human Genetics. (yashar@umich.edu)
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO 08/24/2012 Section: Surgery Place(s) of Service: Inpatient I.
More informationMP Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers
Medical Policy MP 2.04.02 Genetic Testing for BRCA1 or BRCA2 for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk BCBSA Ref. Policy: 2.04.02 Last Review: 11/15/2018 Effective Date: 02/15/2019
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationUnderstanding Your Genetic Test Result. Positive for a Deleterious Mutation or Suspected Deleterious
Understanding Your Genetic Test Result Positive for a Deleterious Mutation or Suspected Deleterious This workbook is designed to help you understand the results of your genetic test and is best reviewed
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics
GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review
More informationFactors Associated with Early Versus Late Development of Breast and Ovarian Cancer in BRCA1 and BRCA2 Positive Women
Texas Medical Center Library DigitalCommons@The Texas Medical Center UT GSBS Dissertations and Theses (Open Access) Graduate School of Biomedical Sciences 5-2010 Factors Associated with Early Versus Late
More informationProphylactic Mastectomy
Prophylactic Mastectomy Policy Number: Original Effective Date: MM.06.010 01/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 12/01/2013 Section: Surgery Place(s) of Service:
More informationOriginal Policy Date
MP 7.01.06 Prophylactic Mastectomy Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationOBJECTIVES 8/25/2017. An attempt to organize the chaos
High Risk for Breast Cancer and Genetics: Who? What? Where? When? An attempt to organize the chaos Presented at Winds of Change Conference November 3, 2017 by Carol Hager, MSN, CRNP and Allison Haener,
More informationMastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data
Mastectomy For Treatment, For Prevention, For Prophylaxis Not as Simple as Following Data Nathalie Johnson, MD FACS Medical Director, Legacy Cancer Institute and Breast Health Centers Objectives Understand
More informationOriginal. Mayuko INUZUKA 1 2, Takashi KUWAYAMA 1 3, Terumasa SAWADA 1 3, Sadako AKASHI-TANAKA 1 3 and Seigo NAKAMURA 1 3
Showa Univ J Med Sci 30 1, 87 96, March 2018 Original Satisfaction with Decision Regarding BRCA1/2 Genetic Testing and Willingness to Undergo BRCA1/2 Genetic Testing in the Future Among Breast Cancer Patients
More informationUpdates in Cancer Genetics & Genomics
Updates in Cancer Genetics & Genomics Jennifer R. Klemp, PhD, MPH, MA Associate Professor of Medicine, Division of Clinical Oncology Director, Cancer Survivorship Co-Program Leader, Cancer Prevention and
More informationProphylactic mastectomy, a look at the problem
www.clinicaloncology.com.ua 1 Prophylactic mastectomy, a look at the problem I.I.Smolanka, S.Y.Skliar, A.D.Loboda The National Cancer Institute, Kiev Summary: The question of the bilateral prophylactic
More informationTreatment issues for women with BRCA germline mutation
Treatment issues for women with BRCA germline mutation Overview Fertility and reproductive lifespan The impact of reproductive life on breast and ovarian cancer risk Screening recommendations during pregnancy
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationNHOLUA. September 20, 2016 Lincoln, NE
NHOLUA September 20, 2016 Lincoln, NE UNDERWRITING BREAST CANCER, A NEW APPROACH Dr Robert Lund Basics in Determination of Breast Cancer Prognosis Age at Diagnosis Tumor Size Lymph Node Status Title of
More informationRole of genetic testing in familial breast cancer outside of BRCA1 and BRCA2
Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Introduction Most commonly diagnosed cancer in South African women and the second most commonly diagnosed cancer in Black women
More informationPrimary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationJill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania
Jill Stopfer, MS, CGC Abramson Cancer Center University of Pennsylvania Aging Family history Early menarche Late menopause Nulliparity Estrogen / Progesterone use after menopause More than two alcoholic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
BRCA1 and BRCA2 Testing Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: BRCA1 and BRCA2 Testing Pre-Determination of Services IS REQUIRED by the Member
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationBRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI
BRCA1 & BRCA2: CANCER RISK & GENETIC TESTING IAP ID 2013 NAIR HOSPITAL, MUMBAI DR KIRTI CHADHA MD (Path), PDCC (Oncopath & Oncohemat) CONSULTANT SURGICAL PATHOLOGIST NATIONAL COORDINATOR,SURGICAL PATHOLOGY
More informationNotes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina
Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to finally be able to put these genomics related data items
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More information6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention
6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION. Women who carry a germline mutation in
VOLUME 22 NUMBER 12 JUNE 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers Kelly Metcalfe, Henry T. Lynch, Parviz Ghadirian,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Prophylactic Mastectomy Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Prophylactic Mastectomy Professional Institutional Original Effective Date:
More informationpatient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015
patient education Fact Sheet PFS007: BRCA1 and BRCA2 Mutations MARCH 2015 BRCA1 and BRCA2 Mutations Cancer is a complex disease thought to be caused by several different factors. A few types of cancer
More informationGenetic Counseling: Dealing with Uncertainty. Kathy J. Helzlsouer, MD, MHS Epidemiology and Genomics Research Program, DCCPS, NCI August 17, 2017
Genetic Counseling: Dealing with Uncertainty Kathy J. Helzlsouer, MD, MHS Epidemiology and Genomics Research Program, DCCPS, NCI August 17, 2017 2 Multiple Paths to Genetic Counseling/Testing Family history
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationModelling cancer risk predictions:clinical practice perspective.
Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult
More informationMedical Policy POLICY POLICY GUIDELINES. MP Prophylactic Mastectomy
Medical Policy MP 7.01.09 Last Review: 7/25/2017 Effective Date: 11/01/2017 Issue: 7:2017 Related Policies: 2.04.02 Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome (BRCA1 or BRCA2) 2.04.93
More informationInherited Ovarian Cancer Diagnosis and Prevention
Inherited Ovarian Cancer Diagnosis and Prevention Dr. Jacob Korach - Deputy director Gynecologic Oncology (past chair - Israeli Society of Gynecologic Oncology) Prof. Eitan Friedman - Head, Oncogenetics
More informationGenetic Screening Visit
Before your visit In a typical hereditary breast ovarian cancer genetic counsling visit be prepared to answer the following set of questions, please check were applicable. About your self (same questions
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More information30 TPHA Journal Volume 65, Issue 2
Utilization of BRCA testing in older women with breast and/or ovarian cancer in the state of Texas Ana M. Rodriguez,¹ Sharon H. Giordano,² and Catherine D. Cooksley³ ¹Department of Obstetrics & Gynecology,
More informationGenetic counseling and testing. Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel
Genetic counseling and testing Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau, honoraria, consultancy Astra
More informationGenetic Panel Testing and Implications for Cancer Care
Genetic Panel Testing and Implications for Cancer Care Dana Zakalik, M.D. Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Board of Directors Meeting September 28, 2016
More informationMultidisciplinary approach to Young Breast Cancer Nursing. Department of Surgery, Soonchunhyang University, Cheonan Hospital Eunju Lee
Multidisciplinary approach to Young Breast Cancer Nursing Department of Surgery, Soonchunhyang University, Cheonan Hospital Eunju Lee I have nothing to disclose. No relevant financial relationships with
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationSporadic Cancer - Cancer which occurs by chance. People with sporadic cancer typically do not have relatives with the same type of cancer.
to risk assessment Hereditary Cancer Testing: Is it Right for You? This workbook is designed to help you decide if hereditary cancer testing is right for you and should be reviewed with a trained healthcare
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationApplies to: All Aetna plans, except Traditional Choice plans. All Innovation Health plans, except indemnity plans
BRCA Precertification Information Request Form Applies to: All Aetna plans, except Traditional Choice plans All Innovation Health plans, except indemnity plans All Health benefits and health insurance
More informationTumori eredofamiliari: sorveglianza di donne ad alto rischio
Tumori eredofamiliari: sorveglianza di donne ad alto rischio 14/01/2018 Dott Matteo Generali AUSL Modena Carpi U.O. Ostetricia e Ginecologia Screening for gynaecologic cancer in genetically predisposed
More informationPolicy #: 259 Latest Review Date: November 2009
Name of Policy: Prophylactic Oophorectomy Policy #: 259 Latest Review Date: November 2009 Category: Surgery Policy Grade: Active Policy but no longer scheduled for regular literature reviews and updates.
More informationPATIENT AND GENETICS HEALTHCARE PROVIDER ATTITUDES REGARDING RECONTACT. Michelle Rose O Connor. BS, The Ohio State University, 2012
PATIENT AND GENETICS HEALTHCARE PROVIDER ATTITUDES REGARDING RECONTACT by Michelle Rose O Connor BS, The Ohio State University, 2012 Submitted to the Graduate Faculty of the Department of Human Genetics
More informationBreast Cancer Risk Assessment: Genetics, Risk Models, and Screening. Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center
Breast Cancer Risk Assessment: Genetics, Risk Models, and Screening Amie Hass, MSN, ARNP, FNP-BC Hall-Perrine Cancer Center Disclosure- I DO NOT HAVE any relevant financial interest with any entity producing,
More informationAllinaHealthSystems 1
Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective
More informationHereditary Prostate Cancer: From Gene Discovery to Clinical Implementation
Hereditary Prostate Cancer: From Gene Discovery to Clinical Implementation Kathleen A. Cooney, MD MACP Duke University School of Medicine Duke Cancer Institute (No disclosures to report) Overview Prostate
More information